Drugs / CD276 CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT04691713 | Sep 2019 → Feb 2021 | cancer | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD276 CAR-T | “CD276 CAR-T for Patients With Advanced CD276+ Solid Tumors” NCT04691713 ↗ |
| Action | Deplete | “use the patient's own immune cells to clear cancer cells” NCT04691713 ↗ |
| Modality | Cell therapy | “Chimeric antigen receptor T cells (car-t)” NCT04691713 ↗ |
| Target | CD276 | “targeting CD276 auto-chimeric antigen receptor T cells” NCT04691713 ↗ |